Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies

Read MoreHide Full Article

For Immediate Release

Chicago, IL – February 27, 2024 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , Salesforce, Inc. (CRM - Free Report) , Vertex Pharmaceuticals Inc. (VRTX - Free Report) , Palo Alto Networks, Inc. (PANW - Free Report) and The Williams Companies, Inc. (WMB - Free Report) .

Here are highlights from Monday’s Analyst Blog:

Top Stock Reports for JPMorgan, Salesforce and Vertex Pharma

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., Salesforce, Inc. and Vertex Pharmaceuticals Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Shares of JPMorgan Chase have outperformed the Zacks Banks - Major Regional industry over the past year (+33.1% vs. +11.9%). High interest rates, buyouts, opening new branches and decent loan demand will aid net interest income (NII), though rising funding costs will weigh on it.

Despite some green shoots in the investment banking (IB) business, IB fees are less likely to improve anytime soon. This, along with the volatile nature of the capital markets business and high mortgage rates, will likely hamper fee income growth.

(You can read the full research report on JPMorgan Chase here >>>)

Shares of Salesforce have outperformed the Zacks Computer - Software industry over the past year (+79.5% vs. +59.8%). The company is benefiting from a robust demand environment as customers are undergoing a major digital transformation. Salesforce's sustained focus on aligning products with customer needs is driving the top line.

Continued deal wins in the international market are another growth driver. The buyout of Slack has positioned the company as a leader in enterprise team collaboration and improved its competitive standing versus Microsoft Teams. Salesforce's strategy of continuously expanding generative AI offerings will help the company tap the growing opportunities in the space.

However, stiff competition and unfavorable currency fluctuations are concerns. Also, the challenging macroeconomic environment could hurt its growth prospects.

(You can read the full research report on Salesforce here >>>)

Shares of Vertex Pharmaceuticals have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+49.7% vs. -6.1%). The company's cystic franchise sales continue to grow, driven by its triple therapy, Trikafta/Kaftrio. New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving Trikafta/Kaftrio sales higher.

Vertex saw rapid success in its non-CF pipeline candidates' development in 2023. Its one-shot gene therapy, Casgevy, was approved for two blood disorders in multiple regions, which diversified its commercial opportunity.

Vertex is on track to submit regulatory applications for VX-548 in acute pain and for vanzacaftor triple in CF by mid-2024. Vertex faces minimal competition in its core CF franchise.

(You can read the full research report on Vertex Pharmaceuticals here >>>)

Other noteworthy reports we are featuring today include Palo Alto Networks, Inc. and The Williams Companies, Inc.

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Published in